Additional file 3: of α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Figure S1. Growth responses of CCK62 and GEK1428 to immunotherapy. Figure S2. CCK168 responses to α-PD-1 and/or α-TGFβ. Figure S3. α-TGFβ and α-TGFβ/α-PD-1 combination therapy elicit long-term tumor immunity to Kras-driven tumors. Figure S4. Gating strategy for T cell flow cytometry and analysis of differentiation and proliferation markers. Figure S5. Gating strategy for Th versus Treg cell flow cytometry and analysis of differentiation and proliferation markers. Figure S6. Gating strategy for myeloid cell flow cytometry and analysis of macrophage and dendritic cell markers. Figure S7. Depletion of Tregs 24 hours after anti-CD25 antibody treatment. Figure S8. α-PD-1 induces pSmad3 in CCK168 cells. Figure S9. CD3 T cell staining and histology of tumors after treatment with each of the four drug arms as indicated. Figure S10. IHC analysis of immune infiltrates in tumors. (PDF 9660 kb